In Vitro Induction Studies: Elements of Design and Important Considerations in Data Analysis

1,808 views

|

April 24, 2019

Webinar Originally Aired: 24 April 2019
Presenter: Joanna Barbara, Ph.D., Vice President of Scientific Operations at SEKISUI XenoTech

Synopsis:
When evaluating drug-drug interaction (DDI) risk of an investigational drug, a battery of studies is needed to investigate victim/perpetrator potential. One of these comprises evaluation of the potential of a new therapy to induce drug-metabolizing enzymes, which can impact clearance of concomitantly administered drugs. The team at SEKISUI XenoTech has built a reputation of dedicating high quality resources and specialists to conduct such studies with scientific rigor.

In this webinar, Dr. Joanna Barbara will address frequently asked questions from sponsors seeking induction studies and elaborate on some recommendations we give to achieve successful regulatory submission. Points of discussions will include an overview of enzyme induction studies and critical considerations in design, from determination of supporting data to conclusive interpretation.

Key concepts discussed in this webinar will include:
• Standard study considerations
• FDA guidance requirements
• Required endpoints for IND submission
• 3A induction and associated challenges
• Next-step recommendations...

Download a copy of the slides: https://www.xenotech.com/webinars/webinar-registration-in-vitro-induction-studies
Questions, comments and requests: https://www.xenotech.com/contact-us
More information on our enzyme induction services: https://www.xenotech.com/services/enzyme-induction
Other previously aired webinars: https://www.xenotech.com/scientific-resources/webinar-series
Upcoming webinars: https://www.xenotech.com/scientific-resources/webinar-series/request-a-webinar

DiagnosticsDrug DiscoveryGenomicsMass Spectrometry

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.